cerca CERCA
Venerdì 15 Gennaio 2021
Aggiornato: 16:41


JUD care Obtains FDA Approval for Its Portable Ward sRoom

SHENZHEN,China, Jan. 12, 2021 /PRNewswire/ -- JUD care, a leading high-tech enterprise in the field of smart medical and healthcare solutions, has obtained approval from the US Food and Drug Administration (FDA) for the portable ward sRoom ("sRoom"), a revolutionary solution for patient isolation that enables hospitals to quickly set up emergency isolation rooms.

Polyplastics Targets PBT and PPS Grades in Sensors for Autonomous Driving Applications

TOKYO, Jan. 12, 2021 /PRNewswire/ -- The growing trend toward electric vehicles is spurring materials suppliers like Polyplastics Co., Ltd., a leading global supplier of engineering plastics, to position its innovative resin products for use in Advanced Driver-Assistance System(ADAS) parts that enable autonomous driving. The company's DURANEX(R) PBT and DURAFIDE(R) PPS materials--targeted for sensors in radar and camera bracket systems--show great promise in delivering low warpage, dimensional st...

Caprion-HistoGeneX Acquires Clinical Logistics Inc., a Virtual Central Specimen Management CRO, and Expands its Support of Clinical Trials Specimen Logistics

MONTREAL, Jan. 7, 2021 /PRNewswire/ -- Caprion-HistoGeneX, a leading global contract research laboratory services provider backed by Arsenal Capital Partners, announced today the acquisition of Clinical Logistics Inc. ("CLI"), a Virtual Central Specimen Management CRO based in Halifax, Canada. The acquisition enables Caprion-HistoGeneX to broaden its specimen logistics services to support the global clinical trial needs of its pharma and biotech customers better. Focused on critical specialty spe...

Winhealth Pharma and TWiB Enter into Strategic Licensing Partnership on AC-203

SHANGHAI and TAIPEI, Jan. 7, 2021 /PRNewswire/ -- Hongkong Winhealth Pharma Group (Winhealth Pharma) and Taiwan TWi Biotechnology, Inc. (TWiB) announced strategic partnership granting Winhealth Pharma exclusive right to develop and commercialize rare disease asset AC-203 in mainland China, Hong Kong and Macao for indications including hereditary epidermolysis bullosa (EB), bullous pemphigoid and other skin diseases.

WinHealth and Immedica enter agreement giving Winhealth rights to Ravicti® in China and several other Asia-Pacific countries

STOCKHOLM and HANGZHOU, China, Dec. 31, 2020 /PRNewswire/ -- Hongkong WinHealth Pharma Group CO., Ltd and Immedica Pharma AB, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti® (glycerol phenylbutyrate), in a territory covering the Greater China Area, South Korea, Singapore, Vietnam, Indonesia, Malaysia, Philippines and Thailand.

Plasticase/NANUK annuncia il nuovo direttore vendite e della strategia commerciale dell'EMEA

GRONINGEN, Paesi Bassi, 17 dicembre 2020 /PRNewswire/ -- Il Presidente e CEO di Plasticase Inc., José Chagnon e Herman Vaszlovsky, Amministratore Delegato di NANUK EU bv, hanno oggi annunciato la nomina di Ken Adriaenssens a Direttore Vendite e Strategia Commerciale dell'EMEA. Plasticase Inc. è il produttore di valigie protettive professionali NANUK con sede in Quebec, Canada.

Yiling Pharmaceutical: TCM Lianhua Qingwen Obtained Access to Zimbabwe

SHIJIAZHUANG, China, Dec. 17, 2020 /PRNewswire/ -- Yiling Pharmaceutical discloses on Wednesday that it has received the Approval of Registration approved and issued by the Medicines Control Authority of Zimbabwe, which indicates that the Company's patented product of "Lianhua Qingwen Capsules" meets Zimbabwe's registration standards for complementary medicine. 

Plasticase/NANUK Announces New EMEA Director of Sales and Commercial Strategy

GRONINGEN, The Netherlands, Dec. 15, 2020 /PRNewswire/ -- President and CEO of Plasticase Inc., José Chagnon and Herman Vaszlovsky, Managing Director of NANUK EU bv, today announced the appointment of Ken Adriaenssens as EMEA Director of Sales and Commercial Strategy. Plasticase Inc. is the Quebec, Canada-based manufacturer of NANUK Professional Protective Cases.

The EspeRare Foundation and Pierre Fabre join forces to develop and market a pioneering treatment for XLHED, a dermatologic-related rare genetic disease that requires prenatal therapeutic intervention

GENEVA and CASTRES , France, Dec. 14, 2020 /PRNewswire/ -- The EspeRare Foundation and the Pierre Fabre group announced today that they have entered into a license and development collaboration agreement for the development and commercialization of ER-004, a prenatal treatment for XLHED (X-linked Hypohidrotic Ectodermal Dysplasia), a rare, debilitating congenital disease. The next clinical study is expected to start in 2021 and will aim at qualifying and registering what may become the first appr...

ora in
Prima pagina
Tag più usati
in questa pagina


press release


aziende informano






in Evidenza